MarginsXMarginsX
Home › Markets › Health Care › TLX

Telix Pharmaceuticals Limited (TLX)

TLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.92
-3.36% on the day
Market cap
$3.0B
Mid cap
Revenue · 2025
$803.8M
+55.6% on 2024
Net income · 2025
-$7.1M
-0.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/0001628280-26-009943-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTLX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryAustralia
IPO yearNot reported by the screener
SEC CIK0002007191
SEC industry codePharmaceutical Preparations
Incorporated inAustralia

Financials · 2025

LineValue
Revenue$803.8M
Net income-$7.1M
Operating income$29.8M
Net margin-0.9%
Operating margin3.7%
Revenue growth+55.6%
Cash$141.9M
Total assets$1.2B
P/E (computed)Net income was not positive
P/S (computed)3.8×

Warning signs

Cash runway
98.4 months
$141.9M cash at December 31, 2025
Share count, 1 year
+1.2%
2024-12-31 to 2025-12-31
Going-concern doubt
No
20-F filed February 20, 2026
Insider net buying, 12 months
$1.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-20
Cash and burn$141.9M cash; operating cash flow -$4.3M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers, Melbourne, AustraliaPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.0M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$803.8M-$7.1M-$17.3M$141.9M$405.0M$803.8M20-F 2026-02-20
FY 2024
2024-12-31
$516.6M$33.7M$27.5M$440.0M$353.6M$516.6M20-F 2026-02-20
FY 2023
2023-12-31
$333.0M$4.2M$14.3M$84.3M$6.6M$333.0M20-F 2026-02-20

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentDRS2024-09-13
Latest annual report20-F2026-02-20
Latest quarterly / interim6-K2026-10-29

Source: SEC EDGAR submissions feed, 109 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.2%
1 month-15.5%
3 months-25.1%
Year to date+23.2%
1 year-2.9%
From 52-week high-28.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
XERSXeris Biopharma Holdings Inc.$16.70+0.24%$3.1B
LEGNLegend Biotech Corporation$15.99-8.63%$3.1B
IDYAIDEAYA Biosciences Inc.$30.36-4.62%$2.9B
DYNDyne Therapeutics Inc.$16.70-2.68%$3.1B
BHCBausch Health Companies Inc.$8.42+0.84%$3.2B
VCREVicore Pharma Holding AB$10.16-1.93%$2.9B
ACADACADIA Pharmaceuticals Inc.$18.67-0.43%$3.2B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier